Is SNN a Buy or a Sell? The Bull and Bear Case (2026)

The most optimistic published target on SNN is $38.00, +29.9% from the $29.26 price as of August 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

The most pessimistic published target is $30.00, +2.5% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Smith & Nephew is worth if the risks below bite instead of the drivers above.

The clearest risk is that US Orthopaedics does not turn. Knee implants fell 7.2% in the US in the second quarter of 2026 and the fix depends on launches, principally LANDMARK and wider LEGION MS set deployment, that mostly land in 2027. Launches slip, surgeons switch slowly, and a competitor with four times the revenue can out-spend the response. Advanced Wound Bioactives is the second pressure point: revenue fell 8.1% underlying in the first half after the January 2026 US reimbursement reset on skin substitutes, and the full-year headwind is now expected toward the upper end of a $20 million to $40 million range. China is a third. Volume-based procurement has already compressed sports medicine pricing, the ENT tender process has been delayed into the second half of 2026, and the company has been running down channel inventory ahead of it, so the reported growth in that market is not a clean read on demand. Execution risk sits on top of all of it: hitting full-year guidance now requires second-half growth of 5.0% to 5.5% against 2.3% delivered in the first half. There is a governance gap as well. CFO John Rogers resigned on August 19, 2026 and leaves on September 30 with a search under way, and Pierre Palassian is interim. Cevian's 14.2% position could force portfolio action or leave a large overhang if the thesis is abandoned. Legacy metal-on-metal hip claims still carry provisions, adjusted net debt to EBITDA was 1.8 times at the half, and $350 million of corporate bonds plus $140 million of private placement debt fall due in the first half of 2027.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding SNN already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.

5 analysts cover SNN, with an average target of $33.66 (+15.0% against $29.26) and a split of 2 buy, 3 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the SNN forecast and price target page.

• Revenue (TTM): ~$6.30 billion for the twelve months to June 27, 2026, derived from 2025 revenue of $6,164 million plus first-half 2026 revenue of $3,097 million less first-half 2025 revenue of $2,961 million. Full-year 2025 revenue grew 6.1% reported and 5.3% underlying, from $5,810 million in 2024 and $5,549 million in 2023. First-half 2026 growth was 4.6% reported but only 2.3% underlying, with a 230 basis point currency tailwind and one fewer trading day. Everything here is reported in US dollars, the company's actual reporting currency, so no conversion from sterling is involved.
• Earnings and adjusted earnings: Attributable profit of ~$635 million for the twelve months to June 27, 2026, giving basic EPS of ~74.2 cents per ordinary share, or roughly $1.48 per ADS at the two-for-one ratio. Full-year 2025 EPS was 72.1 cents, up 52.8%, on operating profit of $794 million. The company's preferred measure runs well above that: trading profit was $1,211 million in 2025 (19.7% margin) and ~$1,254 million on a trailing basis, with adjusted EPS of 102.0 cents per ordinary share in 2025 and ~106.8 cents trailing, about $2.14 per ADS. The gap between operating and trading profit, roughly $440 million, is restructuring, acquisition amortisation and legal items.
• Franchise mix and margins: 2025 revenue split Orthopaedics $2,437 million, Sports Medicine & ENT $1,934 million and Advanced Wound Management $1,793 million, with segment trading margins of 14.9%, 23.8% and 24.9% respectively. In the first half of 2026 that became Orthopaedics $1,213 million (down 0.1% underlying, 13.0% margin), Sports Medicine & ENT $1,017 million (up 7.7%, 24.7% margin) and Advanced Wound Management $867 million (down 0.1% underlying, 22.0% margin). Geographically, US revenue was $1,591 million of the $3,097 million half, other established markets $958 million, and emerging markets $548 million growing 10.6% underlying.
• Cash flow and balance sheet: Free cash flow of ~$823 million on a trailing basis, after $836 million in 2025 against a $625 million internal target. First-half 2026 cash from operations was $605 million, up 6.9%, while free cash flow slipped to $231 million on ~$51 million of extra capex for a new UK wound factory and IT upgrades. Net debt was $3,019 million at June 27, 2026 (including $197 million of lease liabilities), up from $2,747 million at December 31, 2025, and adjusted net debt to EBITDA was 1.8 times. In June 2026 the group issued a EUR 500 million 4.25% bond due 2038. Nothing matures in the second half of 2026; $350 million of corporate bonds and $140 million of private placement notes fall due in the first half of 2027.
• Market pricing: The ADS traded around $29 in late August 2026, against a 52-week range of ~$28.56 to ~$38.79, close to the low after a 2025 in which the shares rose 28%. There were 840,515,838 ordinary shares outstanding on July 23, 2026, equivalent to roughly 420 million ADSs, for a market capitalisation of ~$12.3 billion and enterprise value of ~$15.3 billion including net debt. On those figures the shares trade at ~20 times trailing reported EPS, ~14 times adjusted EPS, ~2.4 times EV to sales and roughly 9 times EBITDA implied by the disclosed 1.8 times leverage. The 2025 dividend of 39.1 cents per ordinary share (78.2 cents per ADS) is a yield of ~2.7%, and the 2026 interim was raised 4.0% to 15.6 cents.
• Guidance and 2028 targets: Full-year 2026 revenue growth was cut to around 4% from around 6% on August 4, 2026, implying second-half growth of 5.0% to 5.5%. Trading profit guidance was held at around $1.3 billion post-acquisition (roughly 8% growth excluding acquisitions), free cash flow at around $800 million, and adjusted ROIC above 10% excluding Integrity Orthopaedics, funded partly by an extra $50 million of savings taking the 2026 total to around $200 million. The RISE strategy of December 2025 targets a 6% to 7% organic revenue CAGR and 9% to 10% trading profit CAGR through 2028, against 2025 adjusted ROIC of 8.3%.

The multiple sits well below the large-cap orthopaedic peer group, and the reason is visible in the segment table rather than in any accounting subtlety: the largest franchise earns the lowest margin and is not growing. Investors buying at ~14 times adjusted earnings are paying for the RISE targets to close that gap, or for someone to force the issue on portfolio structure.

Rather than asking whether SNN is a buy in the abstract, it tends to help to answer four questions:

• Thesis: do you believe the bull case above, and is it still true today?
• Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
• Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
• Overlap: check whether you already hold SNN indirectly through an index or sector ETF before adding more.

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

• Bull case breaks if: Sports Medicine is doing the compounding stalls in the reported numbers rather than in the narrative around them.
• Bear case breaks if: the clearest risk is that US Orthopaedics does not turn fails to materialise over several reporting periods while the drivers keep compounding.
• Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the SNN stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about SNN against your real portfolio and see your actual exposure before deciding.